Resource impact statement
Cancer Drugs Fund technology
NICE has recommended isatuximab plus pomalidomide and dexamethasone for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults who have had lenalidomide and a proteasome inhibitor, and whose disease has progressed on their last treatment, only if they have had 3 previous lines of treatment.
Isatuximab plus pomalidomide and dexamethasone will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Sanofi have a commercial access agreement that makes isatuximab available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.
The resource impact of isatuximab plus pomalidomide and dexamethasone will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date the managed access agreement expires, January 2023 or when the results of the managed access agreement data collection are available, whichever is sooner. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.
It is estimated that around 500 people per year with relapsed and refractory multiple myeloma that progress after third-line treatment and have previously had lenalidomide and a proteasome inhibitor are eligible for treatment with isatuximab plus pomalidomide and dexamethasone.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: